Horizon's Actimmune gets Fast Track for Friedreich's

Horizon Pharma plc (NASDAQ:HZNP) gained $1.16 to $28.48 on Friday after FDA granted Fast Track designation to Actimmune interferon (IFN) gamma-1b to treat Friedreich's ataxia.

Horizon expects to begin a Phase III trial in the indication this quarter. Actimmune has Orphan drug designation for Friedreich's ataxia. ...